H7K(R2)2-modified pH-sensitive self-assembled nanoparticles delivering small interfering RNA targeting hepatoma-derived growth factor for malignant glioma treatment

Zhou, Meiling; Jiang, Nan; Fan, Junting; Fu, Song; Luo, Honghua; Su, Ping; Zhang, Mingwan; Shi, Huihui; Zeng, Jiaqi; Huang, Yuan; Yang, Li; Shen, Hong; Zhang, Aixia; Li, Rui

doi:10.1016/j.jconrel.2019.08.010

Cited by 17 publications

(11 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fact that HDGF is a representative member of a gene family ( Figure 1; Figure 2) might be advantageous when we consider it as a therapeutic target. Recently, the significant roles of HDGF in malignant diseases were reported for many non-digestive malignant diseases, including osteosarcoma [61,62], endometrial cancer [63,64], lung cancer [65][66][67], malignant glioma [68][69][70], cervical cancer [71], ovarian cancer [72] and breast cancer [73]. Thus, HDGF is considered as a potential target molecule for anticancer therapy.…”

Section: Hdgf As a Potential Target Molecule For Anticancer Therapymentioning

confidence: 99%

Hepatoma-Derived Growth Factor: An Overview and Its Role as a Potential Therapeutic Target Molecule for Digestive Malignancies

Enomoto

Nakamura

Nishikawa

et al. 2020

IJMS

View full text Add to dashboard Cite

Hepatoma-derived growth factor (HDGF) was identified in research seeking to find a novel growth factor for hepatoma cells. Subsequently, four HDGF-related proteins were identified, and these proteins are considered to be members of a new gene family. HDGF has a growth-stimulating role, an angiogenesis-inducing role, and a probable anti-apoptotic role. HDGF is ubiquitously expressed in non-cancerous tissues, and participates in organ development and in the healing of damaged tissues. In addition, the high expression of HDGF was reported to be closely associated with unfavorable clinical outcomes in several malignant diseases. Thus, HDGF is considered to contribute to the development and progression of malignant disease. We herein provide a brief overview of the factor and its functions in relation to benign and malignant cells. We also describe its possible role as a target molecule for digestive malignancies.

show abstract

Section: Hdgf As a Potential Target Molecule For Anticancer Therapymentioning

confidence: 99%

Hepatoma-Derived Growth Factor: An Overview and Its Role as a Potential Therapeutic Target Molecule for Digestive Malignancies

Enomoto

Nakamura

Nishikawa

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…2E). [176][177][178][179][180][181][182][183][184][185][186][187] 3 Gene therapy: replacement and silencing…”

Section: Reviewunclassified

Revisiting gene delivery to the brain: silencing and editing

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Research has shown incorporation of weak acids and other pH-sensitive compounds into polymeric NPs can result in drug carriers that are stable at physiological pH while destabilized and precipitated in the tumor microenvironment, resulting in drug delivery [ 76 ]. One group investigating NPs for brain tumor therapy attached H 7 K(R 2 ) 2 , a pH responsive peptide, to the surface of PLGA-based, PEGylated NPs in order to enhance targeting of malignant glioma cells in vivo [ 77 ]. While H 7 K(R 2 ) 2 , remained unexposed under physiological conditions due to hydrophobic interactions between PLGA and the H 7 residues, the acidic tumor environment protonated the imidazole ring of H 7 , thus making the H 7 K(R 2 ) 2 more hydrophilic and selectively exposing the cell-penetrating ligand to glioma cells [ 77 ].…”

Section: General Modificationsmentioning

confidence: 99%

“…One group investigating NPs for brain tumor therapy attached H 7 K(R 2 ) 2 , a pH responsive peptide, to the surface of PLGA-based, PEGylated NPs in order to enhance targeting of malignant glioma cells in vivo [ 77 ]. While H 7 K(R 2 ) 2 , remained unexposed under physiological conditions due to hydrophobic interactions between PLGA and the H 7 residues, the acidic tumor environment protonated the imidazole ring of H 7 , thus making the H 7 K(R 2 ) 2 more hydrophilic and selectively exposing the cell-penetrating ligand to glioma cells [ 77 ]. Similar approaches have been used to modify various polymer cores to selectively “activate” NPs in acidic environments [ 76 , 78 ].…”

Section: General Modificationsmentioning

confidence: 99%

Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches

et al. 2022

View full text Add to dashboard Cite

Translation of novel therapies for brain cancer into clinical practice is of the utmost importance as primary brain tumors are responsible for more than 200,000 deaths worldwide each year. While many research efforts have been aimed at improving survival rates over the years, prognosis for patients with glioblastoma and other primary brain tumors remains poor. Safely delivering chemotherapeutic drugs and other anti-cancer compounds across the blood–brain barrier and directly to tumor cells is perhaps the greatest challenge in treating brain cancer. Polymeric nanoparticles (NPs) are powerful, highly tunable carrier systems that may be able to overcome those obstacles. Several studies have shown appropriately-constructed polymeric NPs cross the blood–brain barrier, increase drug bioavailability, reduce systemic toxicity, and selectively target central nervous system cancer cells. While no studies relating to their use in treating brain cancer are in clinical trials, there is mounting preclinical evidence that polymeric NPs could be beneficial for brain tumor therapy. This review includes a variety of polymeric NPs and how their associated composition, surface modifications, and method of delivery impact their capacity to improve brain tumor therapy.

show abstract

H7K(R2)2-modified pH-sensitive self-assembled nanoparticles delivering small interfering RNA targeting hepatoma-derived growth factor for malignant glioma treatment

Cited by 17 publications

References 46 publications

Hepatoma-Derived Growth Factor: An Overview and Its Role as a Potential Therapeutic Target Molecule for Digestive Malignancies

Hepatoma-Derived Growth Factor: An Overview and Its Role as a Potential Therapeutic Target Molecule for Digestive Malignancies

Revisiting gene delivery to the brain: silencing and editing

Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches

Contact Info

Product

Resources

About